A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL [gavilimomab] When Compared to Atgam [antithymocyte globulin] as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease
Phase of Trial: Phase II/III
Latest Information Update: 02 Oct 2005
At a glance
- Drugs Gavilimomab (Primary) ; Antithymocyte globulin
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 02 Oct 2005 New trial record.